EUCTR2006-006497-17-NL进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-WeekStudy to Evaluate the Efficacy and Safety ofEzetimibe/Simvastatin Versus Atorvastatin in Patients with MetabolicSyndrome and Hypercholesterolemia at High Risk for CoronaryHeart Disease
未提供0 个研究点目标入组 1,120 人开始时间: 2007年5月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patient has a diagnosis of metabolic syndrome and hyperclosterolemia.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with screening lab values/findings outside required ranges.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at Moderately High Risk and High Risk for CHD. - Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus AtorvastatiMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaHypercholesterolemiaEUCTR2007-004448-60-BEMerck Sharp & Dohme BV1,281
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups ofTC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patientswith Major Depressive Disorder Who Exhibit an Inadequate Response toAntidepressant TherapyAdjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapyMedDRA version: 12.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2010-020140-36-SKAstraZeneca AB2,236
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – LipidsHypercholesterolemia or Mixed DyslipidemiaMedDRA version: 9.1 Level: LLT Classification code 10020604 Term: HypercholesterolemiaEUCTR2007-002017-39-DKMerck & Co., Inc.1,250
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patient with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease - NDmetabolic syndrome and hypercholesterolemiaMedDRA version: 6.1 Level: SOC Classification code 10007541EUCTR2006-006497-17-ITMERCK SHARP DOHME1,120
进行中（未招募）
不适用
A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorderAdjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapyMedDRA version: 13.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 13.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2010-019925-33-DEAstraZeneca AB940